Glecaprevir/Pibrentasvir
Brand name: Mavyret
Rank #495 of 500 drugs by total cost
$14.1M
Total Cost
1,011
Total Claims
$14.1M
Total Cost
56
Prescribers
$14K
Cost per Claim
259
Beneficiaries
1,016
30-Day Fills
$252K
Avg Cost/Provider
18
Avg Claims/Provider
About Glecaprevir/Pibrentasvir
Glecaprevir/Pibrentasvir (sold as Mavyret) was prescribed 1,011 times by 56 Medicare Part D providers in 2023, costing the program $14.1M. At $14K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 492 | Enoxaparin Sodium (Enoxaparin Sodium) | $14.2M | 93,202 |
| 493 | Omadacycline Tosylate (Nuzyra) | $14.1M | 1,395 |
| 494 | Binimetinib (Mektovi) | $14.1M | 1,094 |
| 495 | Glecaprevir/Pibrentasvir (Mavyret) | $14.1M | 1,011 |
| 496 | Pacritinib Citrate (Vonjo) | $13.9M | 626 |
| 497 | Olmesartan/Hydrochlorothiazide (Olmesartan-Hydrochlorothiazide) | $13.9M | 246,637 |
| 498 | C1 Esterase Inhibitor, Recomb (Ruconest) | $13.8M | 155 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology